Soon after the discovery that APOL1 polymorphisms account for a substantial fraction of the increased risk of kidney disease in people of sub-Saharan African descent [1, 2], there were reports that the APOL1 genotype of kidney donors [14], but not transplant recipients [13], was strongly associated with worse allograft outcomes and donated organs with two APOL1 risk variant alleles have shorter survival compared to organs with one or no risk variant alleles. The gene discussed is APOL1; the disease is kidney disorder.